There is no evidence that liposuction causes cancer. No clinical studies have established a causal link between the procedure and the development of any type of cancer, and the inflammatory response triggered by liposuction is transient, resolving without the kind of chronic oxidative stress associated with cancer risk. That said, the question has more layers than a simple yes or no, particularly for people with a history of breast cancer or those planning fat transfer procedures after liposuction.
What the Clinical Evidence Shows
Liposuction is one of the most studied cosmetic procedures in the world, and cancer has never appeared as a long-term complication in outcome data. The surgery involves suctioning fat cells from beneath the skin, and the physical trauma it creates is localized and heals within weeks. Research on the body’s inflammatory response to cosmetic liposuction confirms that the procedure causes only a short-lived spike in inflammation markers, without progressing to the chronic inflammatory state that can contribute to cancer development over time.
The chemicals used during the procedure, primarily a diluted solution of local anesthetic and a blood vessel constrictor, have not been identified as carcinogenic. While high doses of any drug carry risks, the tumescent fluid used in modern liposuction has been refined specifically for safety, and no association with cancer has been documented.
Fat Transfer and Breast Cancer Recurrence
The more nuanced question isn’t whether liposuction itself causes cancer, but whether fat harvested through liposuction and then injected elsewhere (a procedure called lipofilling or fat grafting) could trigger a recurrence in breast cancer survivors. This concern has driven significant research over the past decade, and the results are reassuring for most patients.
A large retrospective study of 412 women, including 109 who received fat injections after breast cancer treatment, found that lipofilling was not a predictive factor for cancer recurrence, overall survival, or distant metastasis. The American Society of Plastic Surgeons highlighted a controlled study showing locoregional recurrence rates of 1.3% in women who had fat transfer versus 2.4% in women who did not. Distant recurrence rates were similarly comparable: 2.4% with fat transfer versus 3.6% without. In other words, the women who received fat injections actually had slightly lower recurrence rates, though the difference wasn’t statistically meaningful.
Multiple additional studies have confirmed these findings. One placed the hazard ratio for disease recurrence with fat transfer at 0.99, essentially identical to the baseline risk. Another found local recurrence rates of just 1.1% and distant metastasis rates of 2.2% following fat grafting, consistent with expected rates in breast cancer survivors regardless of reconstruction method. A five-year follow-up showed locoregional recurrence of 1.6% in fat transfer patients compared to 4.1% in controls.
There is one exception worth noting. Women on hormone therapy showed a small but statistically significant increase in locoregional recurrence after lipofilling: 1.4% compared to 0.5% in those who did not have the procedure. This is a narrow finding, but it’s the kind of detail your surgical team would factor into your reconstruction plan.
The Stem Cell Concern
Fat tissue contains a type of stem cell that has raised theoretical concerns in laboratory research. These adipose-derived stem cells are naturally present in harvested fat, and lab studies have shown they can promote tumor formation when placed directly alongside cancer cells. In one experiment, these stem cells significantly increased the ability of breast and colon cancer cells to form tumors in mice, while cancer cells alone formed no tumors. The stem cells appeared to activate cancer-promoting pathways and upregulate markers associated with tumor growth.
This sounds alarming in isolation, but it’s important to understand the gap between a lab dish and a human body. The concentrations used in these experiments don’t reflect what happens during a clinical fat transfer. When researchers have looked at actual patient outcomes rather than cell cultures, the recurrence rates described above show no meaningful increase. The American Society of Plastic Surgeons has stated that fat enriched with these stem cells shows recurrence rates of 3.7%, comparable to the 4.13% seen in control groups. Long-term follow-up studies have found no increased recurrence even with stem cell-enriched fat grafts, including in patients who had undergone radiation therapy.
Still, this laboratory finding is why some oncologists recommend caution with fat transfer in patients who had invasive breast cancer. One study did find that women treated for invasive cancer had a higher hazard ratio for local recurrence after fat grafting (5.06), even though the overall population showed no increased risk. The distinction between early-stage and invasive disease matters here.
Fat Necrosis Can Mimic Cancer on Imaging
One practical concern after liposuction or fat transfer is that the procedure can create changes in tissue that look suspicious on mammograms and ultrasounds. When transferred fat doesn’t receive enough blood supply, it dies and forms what’s called fat necrosis. This is a completely benign process, but it can be remarkably difficult to distinguish from cancer on imaging.
In its early stages, fat necrosis appears as a fluid-filled cyst that’s usually easy to identify. As it evolves, though, fibrous tissue replaces the dead fat and can form irregular, spiculated densities on mammography, which is exactly what breast cancer looks like. Fat necrosis can also produce clustered calcifications that are indistinguishable from the calcifications associated with ductal carcinoma, sometimes requiring a biopsy to rule out malignancy. Larger volumes of fat injection increase the likelihood of these changes appearing.
On ultrasound, the limitations are similar. An atypical or ill-defined cystic mass without a clear mammographic match is generally classified as suspicious and flagged for biopsy. MRI offers somewhat better differentiation because fat necrosis typically shows fat signal matching the surrounding breast tissue, a clue that a mass contains dead fat rather than cancer cells. But even on MRI, the inflammatory changes and new blood vessel formation around fat necrosis can mimic the enhancement patterns of malignancy.
This doesn’t mean liposuction or fat transfer causes cancer. It means these procedures can make cancer screening more complicated. If you’ve had liposuction or fat grafting in the breast area, letting your radiologist know before imaging can help them interpret what they see. You may also face a higher likelihood of being called back for additional imaging or biopsy to investigate findings that turn out to be benign.
What This Means for You
If you’re considering liposuction for cosmetic reasons and have no cancer history, the procedure carries no known cancer risk. The body’s response to the surgery is brief and self-resolving, and decades of outcome data support its safety on this front.
If you’re a breast cancer survivor considering fat transfer as part of reconstruction, the overall evidence supports its safety, with recurrence rates that match or fall below those of patients who don’t have the procedure. The exception is women with a history of invasive breast cancer or those on hormone therapy, where the data is more mixed and warrants a detailed conversation with your oncology and surgical teams. Keeping your imaging providers informed about any fat grafting history will help avoid unnecessary anxiety over benign findings that look suspicious on routine screening.